Skip to main content
padlock icon - secure page this page is secure

Editorial [ Advanced Glycation End Products (AGEs) and their Receptor (RAGE) in Health and Disease Executive Editor: Sho-ichi Yamagishi ]

Buy Article:

$68.00 + tax (Refund Policy)

There is a growing body of evidence to show that AGEs, which form and accumulate at an accelerated rate under diabetes and normal aging, are implicated in the pathogenesis of various devastating disorders such as diabetic vascular complications, coronary heart diseases, Alzheimer's disease, cancer growth and metastasis, insulin resistance and nonalcoholic fatty liver disease. In addition, the engagement of the receptor for AGEs, RAGE with the macroprotein derivatives is reported to elicit oxidative stress and vascular inflammation and subsequently activate the downstream signalings, thereby being involved in the development and progression of these devastating disorders. These observations suggest that the AGEs-RAGE axis is a novel therapeutic target for various disorders. In this issue, I would like to reinforce the emerging knowledge regarding AGEs and RAGE as an important mediator in health and disease. I believe that the issue is helpful for most of the researchers and physicians in the field of drug design and clinical pharmacology, especially those who would like to understand the pathophysiological role of the AGEs-RAGE system in health and numerous devastating disorders.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Department of Medicine Kurume University School of Medicine Kurume 830-0011 Japan.

Publication date: April 1, 2008

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more